Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,401 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SoC Clear all
Completed Not applicable Interventional

CGM and DFU Healing Post-discharge

NCT06054659
View directory record Official record
Conditions
Diabetic Foot, Diabetes Type 2 With Diabetic Ulcer of Toe, Skin Breakdown
Interventions
Real Time Continuous Glucose Monitoring (rt-CGM), Fingerstick blood glucose (FBG) monitoring, Diabetes Education
Device · Other · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Completed Not applicable Interventional

Randomized Evaluation of Machine Learning Assisted Radiation Treatment Planning vs Standard Radiation Treatment Planning

NCT05979883
View directory record Official record
Conditions
Cancer Head Neck, Cancer, Head, Cancer Neck
Interventions
Machine Learning Assisted Radiation (MLAP) RapidPlan, Radiation Therapy Standard of Care (SOC)
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Early Introduction and Sustained Ingestion (EISI) Using Two Educational Opportunities in Infants

NCT07321522
View directory record Official record
Conditions
Food Allergy
Interventions
Education and Opportunities on Early Introduction, Clinician Supervised Feeding of Known Allergenic Food
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
4 Months to 11 Months
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Completed Phase 4 Interventional Results available

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma

NCT04677959
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication, Standard of Care Rescue Medication
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
46
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 23, 2026, 5:39 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

NCT06726161
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
RYZ811, RYZ801
Diagnostic Test · Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Recruiting Phase 2 Interventional

Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

NCT07096362
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Interventions
5-Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Gemcitabine, Nab Paclitaxel, Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay
Drug · Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

Tailored Drug Titration Using Artificial Intelligence

NCT04223934
View directory record Official record
Conditions
Hypertension
Interventions
optima4BP
Other
Lead sponsor
Optima Integrated Health
Industry
Eligibility
21 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Completed Not applicable Interventional

CCTG 594: Engagement and Retention in Care for HIV+

NCT01957748
View directory record Official record
Conditions
Patient Adherence, HIV Positive
Interventions
SoC + ALERT Intervention
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 23, 2026, 5:39 PM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

NCT04745351
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, RDV Placebo, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Eureka, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 23, 2026, 5:39 PM EDT
Completed Not applicable Interventional

Enhanced Medical Rehabilitation for Spinal Cord Injury

NCT03952416
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Enhanced Medical Rehabilitation (EMR)
Behavioral
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 23, 2026, 5:39 PM EDT
Active, not recruiting Not applicable Interventional

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

NCT04751747
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Computed Tomography, Contrast Agent
Procedure · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Recruiting Not applicable Interventional

Testing the Effects of Exercise on Colorectal Cancer Development After Treatment With Pelvic Radiation Therapy for Prostate Cancer

NCT07790718
View directory record Official record
Conditions
Colon Polyp, Colorectal Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Aerobic Exercise, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Data Collection, Physical Performance Testing, Questionnaire Administration, Sigmoidoscopy, Survey Administration
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

Mitigation of Major Hip Injury Due to Fall With a Smart Belt

NCT05245097
View directory record Official record
Conditions
Hip Injuries, Fractures, Hip, Fall Injury, Fall Risk, Osteoporosis, Osteoporosis Risk
Interventions
Tango Belt, Standard of Care (SOC)
Device · Other
Lead sponsor
ActiveProtective Technologies, Inc
Industry
Eligibility
65 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Sacramento, California • Bensalem, Pennsylvania • Gwynedd, Pennsylvania + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 23, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718389
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
Biological · Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
1,717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
119
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Active, not recruiting Phase 2 Interventional

Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection

NCT05753215
View directory record Official record
Conditions
Bone Infection, Joint Infection, Bone and Joint Infection
Interventions
Omadacycline Pill, Standard of Care
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

NCT00691015
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV
Biological · Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 23, 2026, 5:39 PM EDT
Active, not recruiting Phase 2 Interventional

A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis

NCT05539963
View directory record Official record
Conditions
Diabetic Foot Osteomyelitis
Interventions
STIMULAN VG, Systemic Antibiotics
Drug
Lead sponsor
Biocomposites Ltd
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 23, 2026, 5:39 PM EDT
Recruiting Phase 2 Interventional

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

NCT07293247
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy, Computed Tomography, Magnetic Resonance Imaging, Fludeoxyglucose F-18, Biospecimen Collection
Drug · Other · Radiation + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
111
States / cities
Jonesboro, Arkansas • Los Angeles, California • Parker, Colorado + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863

NCT01831804
View directory record Official record
Conditions
Wound Healing
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
7
States / cities
Castro Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 23, 2026, 5:39 PM EDT
Terminated Phase 3 Interventional Results available

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

NCT03629249
View directory record Official record
Conditions
Asthma
Interventions
Placebo once daily, QAW039 150 mg once daily, QAW039 450 mg once daily
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 84 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Newport Beach, California • Westminster, California • Winter Park, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 23, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

NCT04948307
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
OXD01 digital therapy, Standard of Care
Device · Other
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Oceanside, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 23, 2026, 5:39 PM EDT
Recruiting Phase 3 Interventional

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

NCT07276399
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil, Cisplatin
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
49
States / cities
Chandler, Arizona • Tucson, Arizona • Fullerton, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 5:39 PM EDT
Completed Not applicable Interventional

Focused Incentive Spirometry Monitoring to Reduce Postoperative Oxygen Therapy and Respiratory Complications After Bariatric Surgery

NCT03010852
View directory record Official record
Conditions
Respiratory Complication
Interventions
Focused incentive spirometer education and monitoring
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 23, 2026, 5:39 PM EDT